

26 September 2025

### Statement Regarding US Pharmaceutical Tariffs

Advance ZincTek Limited ("the Company") provides an update to the market regarding the recent announcement by the United States Administration concerning the imposition of 100% tariffs on certain "branded or patented" Australian pharmaceutical products.

The Company's Managing Director and management have completed an initial review of the announcement and are hopeful that the Company's products are **unlikely to be impacted** by the new tariff regime.

Key information supporting this assessment includes:

- **Product Classification:** The proposed tariffs are specifically targeted at patented or branded pharmaceutical products. The Company's zinc oxide products are considered active pharmaceutical ingredients (APIs) but are **not branded or patented** in the context of these tariffs.
- **Historical Precedent:** The Company has received guidance from trade advisors that its zinc oxide products, along with other APIs, have been historically excluded from similar tariff announcements, reinforcing the view that they are not the intended target of this policy.
- **Operational Contingency:** To mitigate any potential disruption, the Company maintains a strategic inventory position in the United States, holding over 18 months of supply either in-country or in transit. This provides a substantial buffer, ensuring the Company can continue to meet all customer obligations without immediate impact on its US operations.

The Company is closely monitoring the ongoing diplomatic discussions between the Australian and US Governments. While the Company remains hopeful that a swift resolution will be achieved, its current operational and inventory position provides a shield against any potential mid-term volatility.

### Outlook

Based on the information available and the product-specific nature of the tariffs, the Board does not anticipate any material financial impact on the Company's business in FY25. Advance ZincTek will continue to monitor the situation and will inform the market of any significant developments in accordance with its continuous disclosure obligations.

Authorised by:  
Lev Mizikovsky  
Chairman